Is it Time to Dump First Wave BioPharma Inc (FWBI) Stock After it Has Fallen 5.80% in a Week?

Overall market sentiment has been down on First Wave BioPharma Inc (FWBI) stock lately. FWBI receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

First Wave BioPharma Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on FWBI!

See Full FWBI Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With FWBI Stock Today?

First Wave BioPharma Inc (FWBI) stock is trading at $1.95 as of 12:56 PM on Wednesday, Nov 24, a rise of $0.09, or 4.96% from the previous closing price of $1.86. The stock has traded between $1.81 and $2.18 so far today. Volume today is 1,469,019 compared to average volume of 1,411,774. To screen for more stocks like First Wave BioPharma Inc click here.

More About First Wave BioPharma Inc

First Wave BioPharma Inc is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Click Here to get the full Stock Report for First Wave BioPharma Inc stock.